Incyte Corporation
INCY Healthcare Biotechnology
Incyte Corporation’s revenue for fiscal 2025 (year ended December 2025) was $5.1 billion, up 21.2% from fiscal 2024. In the quarter to June 2026, revenue grew 37.7%, EPS grew 39.7%, free cash flow grew 1,829.5% and total debt fell 10.5%, each against the same quarter a year earlier. Member of the S&P 500; revenue growth for ten consecutive years.
Follow INCY
Incyte Corporation (INCY) Free cash flow margin
Incyte Corporation's free cash flow margin over the twelve months to 30 June 2026 was 32.5%, up 6.6 percentage points from fiscal 2025 (25.9%). Over the past ten years it has ranged from −13.3% (fiscal 2017) to 29.3% (fiscal 2019); the current reading is higher than 82% of that period. That is above the Biotechnology industry median of 0.00% and above the Healthcare sector median of 0.00%.
Free cash flow margin, annual
Embed this chart
Annual newest first
| Period | Free cash flow margin | Change (points) |
|---|---|---|
| FY2025 | 25.9% | 20.32 |
| FY2024 | 5.54% | (6.61) |
| FY2023 | 12.2% | (14.13) |
| FY2022 | 26.3% | 7.24 |
| FY2021 | 19.0% | 30.74 |
| FY2020 | −11.7% | (41.00) |
| FY2019 | 29.3% | 15.34 |
| FY2018 | 14.0% | 27.24 |
| FY2017 | −13.3% | (29.96) |
| FY2016 | 16.7% | 8.27 |
Against its own ten years
Free cash flow margin against peers
| Company | Free cash flow margin |
|---|---|
| RPRX Royalty Pharma PLC compare | 51.7% |
| EXEL Exelixis, Inc. compare | 47.6% |
| INCY Incyte Corporation | 32.5% |
| ASND Ascendis Pharma A/S compare | 32.0% |
| ALNY Alnylam Pharmaceuticals, Inc. compare | 17.1% |
| BNTX BioNTech SE Sponsored ADR compare | 16.6% |
| INSM Insmed, Inc. compare | −71.0% |
| GMAB Genmab A/S Sponsored ADR compare | −153.6% |
| ROIV Roivant Sciences Ltd. compare | −10,901.0% |
| Biotechnology industry median | 0.00% |
| Healthcare sector median | 0.00% |
| Market median | 0.00% |
What Free cash flow margin is
Free Cash Flow Margin tells an investor how much of each sale turns into cash the company keeps after paying for investment in its assets.
(Operating Cash Flow + Property, Plant, Equipment Change (Net) + Intangible Assets Change (Net)) ÷ Revenue
More on INCY
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement